An official website of the United States government Here’s how you know

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

In this section: Scientific Meetings, Conferences, and Workshops

FDA Omics Days 2024 - Poster Gallery

Return to FDA Omics Days 2024

Poster Abstract Booklet

Poster Gallery

Posters will be added here a week before the event

#	Poster PDF	Title	Authors	Contact
1		Evaluation of RNA extraction and Illumina NGS library preparation methods to detect viral RNA from different sample matrices	Sayma Afroj¹*, Aaron Scholl¹, Binsheng Gong², Bingjie Li¹, Joshua Xu², Sandip De¹ ¹ FDA/CBER/OTP/OCTHT/DCT2: Center for Biologics Evaluation and Research; Office of Therapeutic Products; Office of Cellular Therapy and Human Tissue CMC; Division of Cell Therapy 2 ² FDA/NCTR/OR/DBB: National Center for Toxicological Research; Office of Research; Division of Bioinformatics and Biostatistics	sayma.afroj@fda.hhs.gov
2		Evaluation of plasma proteome and miRNA changes related to COVID-19 patient severity response	Richard Beger¹*, Li-Rong Yu¹, Tao Han¹, Vikrant Vijay¹, Jinchun Sun¹, Mallikarjun Bidarimath¹, Elysia Masters¹, Tom Schmitt¹, Lisa Pence¹, Kelly Mercer¹, Jessica Hawes Oliphant¹, Heather Smallwood² ¹ FDA/NCTR/OR/DSB: National Center for Toxicological Research; Office of Research; Division of Systems Biology ² University of Tennessee Health Science Center	richard.beger@fda.hhs.gov
3		Investigating the impact of replicates for different food matrices on non-targeted analysis data and results	Karen E. Butler¹*, Erica L. Bakota², Christine M. Fisher¹, Ann M. Knolhoff¹ ¹ FDA/CFSAN/ORS/DAC: Center for Food Safety and Applied Nutrition; Office of Regulatory Science; Division of Analytical Chemistry ² FDA/ORA/ORS/OHAFLO/KCLHAF/CBI: Office of Regulatory Affairs; Office of Regulatory Science; Office of Human & Animal Food Laboratory Operations; Kansas City Human and Animal Food Laboratory; Chemistry Branch I	karen.butler@fda.hhs.gov
4		Metabolite profiles distinguish exposure to Zika and Dengue flaviviruses in human induced pluripotent stem cells (hiPSCs)	Tahira Fatima¹*, Khyati Mehta², Aaron Scholl¹, Bingjie Li¹, Ewy A. Mathé² Sandip De¹ ¹ FDA/CBER/OTP/OCTHT/DCT2/TVBB: Center for Biologics Evaluation and Research; Office of Therapeutic Products; Office of Cellular Therapy and Human Tissue CMC; Division of Cell Therapy 2; Tumor Vaccines and Biotechnology Branch ² National Center for Advancing Translational Sciences	tahira.fatima@fda.hhs.gov
5	Not Available	Whole genome sequencing (WGS) analyses: Room for the benchtop?	Kristina Feye¹*, Danielle Sopovski¹, Javier Revollo², Jaimie Miranda-Colon², Dereje Gudeta¹, Jing Han¹, Steven Foley¹ ¹ FDA/NCTR/OR/DM: National Center for Toxicological Research; Office of Research; Division of Microbiology ² FDA/NCTR/OR/DGMT: National Center for Toxicological Research; Office of Research; Division of Genetic and Molecular Toxicity	kristina.feye@fda.hhs.gov
7		FDA and NIST collaboration: Evaluation of assays and control materials for characterizing animal biotechnology products generated by genome editing	Patricia Kiesler¹*, Natalia Kolmakova¹, Sierra Miller¹, Ayah Shevchenko1, Stella S. Lee², Ashley Cook², Alexis L. Norris², Mayumi F. Miller³, Carlo J. Mercado², Adam L. Moyer², Samantha Maragh¹ ¹ National Institute of Standards and Technology (NIST); Biosystems and Biomaterials Division ² FDA/CVM/ONADE/DABCT: Center for Veterinary Medicine; Office of New Animal Drug Evaluation; Division of Animal Bioengineering and Cellular Therapies ³ FDA/CVM/OAS/DAVR: Center for Veterinary Medicine; Office of Applied Science; Division of Applied Veterinary Research	maria.kiesler@nist.gov
8	Not Available	Multiomics analysis of optimal cryopreservation conditions for the storage of various cell-based therapies	Shweta Kotian¹*, Farhad Farjood², Nathan Boles², John T. Thomas¹, Brigitte L. Arduini², Jeffrey Stern², Sally Temple², Malcolm C. Moos¹ ¹ FDA/CBER/OTP/OCTHT/DCT1/CTTB: Center for Biologics Evaluation and Research; Office of Therapeutic Products; Office of Cellular Therapy and Human Tissue CMC; Division of Cell Therapy 1; Cellular and Tissue Therapy Branch ² Neural Stem Cell Institute (Rensselaer, NY)	shweta.kotian@fda.hhs.gov
9		Large alterations in the genomes of pigs edited using CRISPR-Cas9	Giselle Blanco¹, Christine Deaver¹, Karyn Howard¹, Cong Li¹, Carlo Mercado², Ashley L. Cook², Dhanansayan Shanmuganayagam³, C. Dustin Rubinstein⁴, Adam Moyer², Alexis Norris², Mayumi Miller¹* ¹ FDA/CVM/OAS/DAVR: Center for Veterinary Medicine; Office of Applied Science; Division of Applied Veterinary Research ² FDA/CVM/ONADE/DABCT: Center for Veterinary Medicine; Office of New Animal Drug Evaluation; Division of Animal Bioengineering and Cellular Therapies ³ University of Wisconsin-Madison; Center for Biomedical Swine Research and Innovation ⁴ University of Wisconsin-Madison; Biotechnology Center	mayumi.miller@fda.hhs.gov
10		Evaluation of a targeted amplicon sequencing method for detection of contaminating microorganisms in a probiotic product	Isha Patel¹*, Mark Mammel¹, Jayanthi Gangiredla¹, Amit Mukherjee^1, Carmen Tartera¹ ¹ FDA/CFSAN/OARSA/DMB: Center for Food Safety and Applied Nutrition; Office of Applied Research and Safety Assessment; Division of Molecular Biology	isha.patel@fda.hhs.gov
11		Metagenomic analysis of the microbial community of an experimental hydroponic system growing leafy greens	Seth Commichaux¹, Taylor Richter¹* ¹ FDA/CFSAN/OARSA/DMB: Center for Food Safety and Applied Nutrition; Office of Applied Research and Safety Assessment; Division of Molecular Biology	taylor.richter@fda.hhs.gov
12		Whole genome sequencing (WGS) as an analytical tool in the Pseudomonas aeruginosa in artificial tears outbreak investigation	Allison Rodriguez¹*, Michelle Cockrell², Arthur Pightling³, Shannon Ruelle⁴, Matthew Silverman¹, Thao Kwan² ¹ FDA/ORA/ORS/OMPSLO/WEAC: Office of Regulatory Affairs; Office of Regulatory Science; Office of Medical Products & Specialty Laboratory Operations; Winchester Engineering and Analytical Center ² FDA/ORA/ORS/OMPSLO/IRVLMP: Office of Regulatory Affairs; Office of Regulatory Science; Office of Medical Products & Specialty Laboratory Operations; Irvine Medical Products Laboratory ³FDA/CFSAN/OAO: Center for Food Safety and Applied Nutrition; Office of Analytics and Outreach ⁴ FDA/ORA/ORS/OMPSLO/MPTSS: Office of Regulatory Affairs; Office of Regulatory Science; Office of Medical Products & Specialty Laboratory Operations; Medical Products and Tobacco Scientific Staff	allison.rodriguez@fda.hhs.gov
13		Understanding the host regulatory circuits behind host defense against flavivirus infection	Aaron Scholl¹, Binsheng Gong², Bingjie Li¹, Tahira Fatima¹, Sayma Afroj¹, Joshua Xu², Sandip De¹ ¹ FDA/CBER/OTP/OCTHT/DCT2: Center for Biologics Evaluation and Research; Office of Therapeutic Products; Office of Cellular Therapy and Human Tissue CMC; Division of Cell Therapy 2 ² FDA/NCTR/OR/DBB: National Center for Toxicological Research; Office of Research; Division of Bioinformatics and Biostatistics	aaron.scholl@fda.hhs.gov
15		Untargeted metabolomics and lipidomics in COVID-19 patient plasma reveals severity biomarkers	Richard Beger¹, Li-Rong Yu¹, Tao Han¹, Vikrant Vijay¹, Mallikarjun Bidarimath¹, Elysia Masters¹, Tom Schmitt¹, Lisa Pence¹, Kelly Mercer¹, Jessica Hawes Oliphant¹, Heather Smallwood², Jinchun Sun¹* ¹ FDA/NCTR/OR/DSB: National Center for Toxicological Research; Office of Research; Division of Systems Biology ² University of Tennessee Health Science Center	jinchun.sun@fda.hhs.gov
16		E. coli exploits co-infection with Enterococcus faecalis to enhance biofilm formation and virulence on antimicrobial urinary catheters	Kidon Sung¹*, Miseon Park¹, Ohgew Kweon¹, Alena Savenka², Angel Paredes², Saeed A Khan¹ ¹ FDA/NCTR/OR/DM: National Center for Toxicological Research; Office of Research; Division of Microbiology ² FDA/NCTR/OSC: National Center for Toxicological Research; Office of Scientific Coordination	kidon.sung@fda.hhs.gov
17		Visualizing the evolution of RNA viruses: A web-based platform for tracking genetic and antigenic changes	Kentaro Tohma¹, Arya D. Eskandarian², Joseph A. Kendra¹, Luis V. Santana-Quintero², Jerry Weir¹, Gabriel I. Parra¹ ¹ FDA/CBER/OVRR/DVP: Center for Biologics Evaluation and Research; Office of Vaccines Research and Review; Division of Viral Products; Division of Viral Products ² FDA/CBER/OBPV: Center for Biologics Evaluation and Research; Office of Biostatistics and Pharmacovigilance; High-Performance Integrated Virtual Environment (HIVE)	kentaro.tohma@fda.hhs.gov
18		Baseline proteomic biomarkers for predicting chemotherapy-induced cardiotoxicity in breast cancer patients	Li-Rong Yu¹*, Zhijun Cao¹, Dong Wang¹, Jaclyn R. Daniels¹, Valentina K. Todorova², Issam Makhoul², V. Suzanne Klimberg², Jeanne Wei², Jane P.F. Bai³, Julia T. Lathrop⁴, Majda Haznadar Uskievich⁴, Jinong Jenn Li⁵, Richard D. Beger¹ ¹ FDA/NCTR/OR/DSB: National Center for Toxicological Research; Office of Research; Division of Systems Biology ² University of Arkansas for Medical Sciences ³ FDA/CDER/OTS/OCP/DARS: Center for Drug Evaluation and Research; Office of Translational Science; Office of Clinical Pharmacology; Division of Applied Regulatory Science ⁴ FDA/CBER/OBRR/DETTD: Center for Biologics Evaluation and Research; Office of Blood Research and Review; Division of Emerging and Transfusion Transmitted Diseases ⁵ FDA/CDER/OPQ/OPMA/DPMAIV: Center for Drug Evaluation and Research; Office of Pharmaceutical Quality; Office of Pharmaceutical Manufacturing Assessment; Division of Pharmaceutical Manufacturing Assessment IV	lirong.yu@fda.hhs.gov
21		Dashboard to monitor foodborne pathogen sequences available via NCBI's Pathogen Detection Portal	Maria Balkey¹*, Marc Allard¹, Tina Pfefer¹, Candace Hope Bias¹, Ruth E. Timme¹ ¹ FDA/CFSAN/ORS/DM: Center for Food Safety and Applied Nutrition; Office of Regulatory Science; Division of Microbiology	maria.balkey@fda.hhs.gov
22		PrecisionFDA: A sandbox for innovative collaborative omics advancement	Samuel Westreich^1,2*, Ezekiel Maier^1,3, Adrienne Phifer^1,3, Omar Serang^1,2, Elaine Johanson¹ ¹ FDA/ODT/ODAR/HIS: Office of Digital Transformation; Office of Data, Analytics, & Research; Health Informatics Staff ² DNAnexus ³ Booz Allen Hamilton	swestreich@dnanexus.com
23		Independent FDA analyses of Nirmatrelvir/Ritonavir resistance in the phase 2/3 trials EPIC-HR and EPIC-SR	Jonathan M. O. Rawson¹*, Eric F. Donaldson¹, Julian J. O’Rear¹, Patrick R. Harrington¹ ¹ FDA/CDER/OND/OID/DAV: Center for Drug Evaluation and Research; Office of New Drugs; Office of Infectious Diseases; Division of Antivirals	jonathan.rawson@fda.hhs.gov

Top